Korro Bio stock fell after missing expectations in early stage KRRO-110 trial
I'm PortAI, I can summarize articles.
Korro Bio's stock fell after the KRRO-110 trial failed to meet expected protein levels for alpha-1 antitrypsin deficiency treatment, despite producing some functional protein.
Source: MSN The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments